A detailed history of Jacob Asset Management Of New York LLC transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Jacob Asset Management Of New York LLC holds 34,103 shares of IDYA stock, worth $873,377. This represents 1.3% of its overall portfolio holdings.

Number of Shares
34,103
Previous 39,028 12.62%
Holding current value
$873,377
Previous $917,000 0.33%
% of portfolio
1.3%
Previous 1.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 01, 2023

SELL
$21.07 - $29.77 $103,769 - $146,617
-4,925 Reduced 12.62%
34,103 $920,000
Q2 2023

Aug 10, 2023

SELL
$13.33 - $25.53 $76,087 - $145,725
-5,708 Reduced 12.76%
39,028 $917,000
Q1 2023

May 11, 2023

SELL
$13.49 - $18.72 $37,448 - $51,966
-2,776 Reduced 5.84%
44,736 $614,000
Q4 2022

Feb 14, 2023

SELL
$14.47 - $18.17 $387,173 - $486,174
-26,757 Reduced 36.03%
47,512 $863,000
Q3 2022

Nov 10, 2022

BUY
$9.24 - $15.79 $176,807 - $302,141
19,135 Added 34.71%
74,269 $1.11 Million
Q2 2022

Aug 11, 2022

SELL
$8.28 - $13.88 $64,542 - $108,194
-7,795 Reduced 12.39%
55,134 $761,000
Q1 2022

May 12, 2022

BUY
$11.18 - $24.02 $123,505 - $265,348
11,047 Added 21.29%
62,929 $704,000
Q4 2021

Feb 09, 2022

SELL
$20.95 - $26.88 $56,418 - $72,387
-2,693 Reduced 4.93%
51,882 $1.23 Million
Q3 2021

Nov 12, 2021

BUY
$17.26 - $27.08 $49,622 - $77,855
2,875 Added 5.56%
54,575 $1.39 Million
Q2 2021

Oct 04, 2021

SELL
$17.76 - $24.83 $40,848 - $57,108
-2,300 Reduced 4.26%
51,700 $1.09 Million
Q1 2021

Oct 04, 2021

BUY
$13.48 - $23.77 $242,640 - $427,860
18,000 Added 50.0%
54,000 $1.27 Million
Q4 2020

Oct 04, 2021

BUY
$12.17 - $17.52 $438,120 - $630,720
36,000 New
36,000 $504,000

Others Institutions Holding IDYA

About IDEAYA Biosciences, Inc.


  • Ticker IDYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,067,700
  • Market Cap $1.23B
  • Description
  • IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...
More about IDYA
Track This Portfolio

Track Jacob Asset Management Of New York LLC Portfolio

Follow Jacob Asset Management Of New York LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacob Asset Management Of New York LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jacob Asset Management Of New York LLC with notifications on news.